Login to Your Account



NewCo News: CureFAKtor Tackles Pancreatic Cancer Via FAK/Chemo Combo

By Jennifer Boggs


Wednesday, February 9, 2011
Since it was founded in 2008, CureFAKtor Pharmaceuticals LLC remained under the radar until recent orphan designation for lead product CFAK-C4 in pancreatic cancer – not to mention some impressive preclinical data at the ASCO Gastrointestinal Cancers Symposium last month – put the firm on the map.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription